Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus-A Systematic Review and Meta-analysis

被引：0
|
作者：
Satti, Muniza M.
O'Brien, Timothy
Liew, Aaron
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1108-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Impact of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) on Bowel Preparation for Colonoscopy: A Systematic Review and Meta-Analysis
    Rahman, Syed Hamaad
    Khan, Nihal I.
    Shafique, Nouman
    Qureshi, Mahir
    Mohamed, Islam
    Musallam, Rami
    Akram, Hamza T.
    Hurairah, Abu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S245 - S245
  • [22] What are the early metabolic effects of combining duodenal exclusion and glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy in patients with Type 2 diabetes?
    Sen Gupta, P.
    Amiel, S. A.
    McGowan, B. M.
    Drummond, R. S.
    Bajwa, R. S.
    Blann, A. D.
    Ryder, R. E. J.
    DIABETIC MEDICINE, 2015, 32 : 98 - 98
  • [23] Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Weihao Wang
    Hongyan Liu
    Shumin Xiao
    Shuaihui Liu
    Xin Li
    Pei Yu
    Diabetes Therapy, 2017, 8 : 727 - 738
  • [24] Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Wang, Weihao
    Liu, Hongyan
    Xiao, Shumin
    Liu, Shuaihui
    Li, Xin
    Yu, Pei
    DIABETES THERAPY, 2017, 8 (04) : 727 - 738
  • [25] Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression
    Hariyanto, Timotius Ivan
    Intan, Denny
    Hananto, Joshua Edward
    Putri, Cynthia
    Kurniawan, Andree
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 179
  • [26] Efficacy and safety of IDegLira (combination of insulin degludec plus liraglutide), in insulin-naive patients with type 2 diabetes uncontrolled on GLP-1 receptor agonist (GLP-1RA) therapy
    Linjawi, S.
    Bode, B. W.
    Chaykin, L. B.
    Courreges, J. -P.
    Handelsman, Y.
    Lehmann, L. M.
    Mishra, A.
    Simpson, R. W.
    DIABETOLOGIA, 2015, 58 : S401 - S402
  • [27] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Use Reduces Risk of Early-Onset Colorectal Cancer in Patients with Type 2 Diabetes-Mellitus (T2DM)
    Olasehinde, Temitope
    Cooper, Gregory
    Perez, Jaime A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S329 - S330
  • [28] Patient-Reported Outcomes following Initiation of Glucagon-Like Peptide-1 Receptor AgonistS (GLP-1RA) in PatientS with Type 2 Diabetes-PROGRESS-DIABETES Study
    Brown, Ruth E.
    Abitbol, Alexander
    Bajaj, Harpreet S.
    Khandwala, Hasnain
    Goldenberg, Ronald
    Abdel-Salam, Suzan
    Aronson, Ronnie
    DIABETES, 2018, 67
  • [29] Age-related differences in patients' preferences for profiles of glucagon-like peptide-1 receptor agonist (GLP-1RA) diabetes treatments in the UK: a discrete choice experiment
    Adetunji, O.
    Poon, J. L.
    Davies, E. W.
    Paczkowski, R.
    Curtis, S. E.
    Gentilella, R.
    Boye, K. S.
    Gelhorn, H. L.
    DIABETIC MEDICINE, 2016, 33 : 192 - 192
  • [30] The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
    Madsbad, Sten
    Holst, Jens J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2025,
12345